[REPORT ON THE CLINICAL TESTING OF 2-BENZENESULFONAMIDO-5-(2-METHOXYETHOXY)-PYRIMIDINE (GLYCODIAZIN), A NEW ORAL ANTIDIABETIC].
D035843:Biomedical Research; D004361:Drug Tolerance; D005853:Geriatrics; D007004:Hypoglycemic Agents; D010600:Pharmacology; D011743:Pyrimidines; D000077145:Sulfanilamide; D013424:Sulfanilamides; D013449:Sulfonamides; D014044:Tolbutamide; D014116:Toxicology
D007004:Hypoglycemic Agents; D011743:Pyrimidines; D013424:Sulfanilamides; D013449:Sulfonamides; D000077145:Sulfanilamide; D014044:Tolbutamide; C030986:pyrimidine
ANTIDIABETICS; CLINICAL RESEARCH; DRUG TOLERANCE; GERIATRICS; PHARMACOLOGY; PYRIMIDINES; SULFONAMIDES; TOLBUTAMIDE; TOXICOLOGIC REPORT
BERICHT UEBER DIE KLINISCHE PRUEFUNG DES 2-BENZOLSULFONAMIDO-5(BETA-METHOXYAETHOXY)-PYRIMIDINS (GLYCODIAZIN), EINES NEUEN ORALEN ANTIDIABETICUMS.